Gail T Colbern
Veterinary at Griffin Ave, Sharp Park, CA
License number
Colorado 4266
Issued Date
Feb 11, 1985
Renew Date
Nov 1, 2010
Expiration Date
Oct 31, 2012
Type
Veterinarian
Address
Address
2
400 Griffin Ave, Sharp Park, CA 94044
Sharp Park, CA
Sharp Park, CA
Professional information
Method For Reducing Toxicity Of A Cytotoxic Agent
US Patent:
2002002, Mar 7, 2002
Filed:
Apr 20, 2001
Appl. No.:
09/839918
Inventors:
Gail Colbern - Pacifica CA, US
Karen Steinmetz - San Mateo CA, US
Peter Working - Burlingame CA, US
Alberto Gabizon - Jerusalem, IL
Karen Steinmetz - San Mateo CA, US
Peter Working - Burlingame CA, US
Alberto Gabizon - Jerusalem, IL
International Classification:
A61K009/127, A61K031/7068, A61K031/704, A61K031/513, A61K031/48
US Classification:
424/450000, 514/034000, 514/050000, 514/269000, 514/288000
Abstract:
Methods for reducing the incidence and occurrence of dermal lesions in mammals, particularly human patients, who receive chemotherapy treatment and in the course of such treatment are administered liposomal formulations of cytotoxic agents are provided. Cytotoxic agents typically include doxorubicin, cytarabine, epirubicin, daunorubicin, 5-fluorouracil (5-FU) and vinorelbine. Reduction in the incidence and occurrence of dermal lesions in a patient is achieved by administration of a cytoprotective agent.
Liposome-Entrapped Topoisomerase Inhibitors
US Patent:
6355268, Mar 12, 2002
Filed:
Oct 15, 1999
Appl. No.:
09/419189
Inventors:
James L. Slater - Palo Alto CA
Gail T. Colbern - Pacifica CA
Peter K. Working - Burlingame CA
Gail T. Colbern - Pacifica CA
Peter K. Working - Burlingame CA
Assignee:
Alza Corporation - Mountain View CA
International Classification:
A61K 9127
US Classification:
424450
Abstract:
A composition for administration of a therapeutically effective dose of a topoisomerase inhibitor I or topoisomerase I/II inhibitor is described. The composition includes liposomes having an outer surface and an inner surface defining an aqueous liposome compartment, and being composed of a vesicle-forming lipid and of a vesicle-forming lipid derivatized with a hydrophilic polymer to form a coating of hydrophilic polymer chains on both the inner and outer surfaces of the liposomes. Entrapped in the liposomes is the topoisomerase inhibitor at a concentration of at least about 0. 10 mole drug per mole lipid.
Liposome-Entrapped Topoisomerase Inhibitors
US Patent:
6465008, Oct 15, 2002
Filed:
Oct 19, 2001
Appl. No.:
10/046326
Inventors:
James L. Slater - Palo Alto CA
Gail T. Colbern - Pacifica CA
Peter K. Working - Burlingame CA
Gail T. Colbern - Pacifica CA
Peter K. Working - Burlingame CA
Assignee:
Alza Corporation - Mountain View CA
International Classification:
A61K 9127
US Classification:
424450
Abstract:
A composition for administration of a therapeutically effective dose of a topoisomerase inhibitor I or topoisomerase I/II inhibitor is described. The composition includes liposomes having an outer surface and an inner surface defining an aqueous liposome compartment, and being composed of a vesicle-forming lipid and of a vesicle-forming lipid derivatized with a hydrophilic polymer to form a coating of hydrophilic polymer chains on both the inner and outer surfaces of the liposomes. Entrapped in the liposomes is the topoisomerase inhibitor at a concentration of at least about 0. 10 mole drug per mole lipid.
Liposome-Entrapped Topoisomerase Inhibitors
US Patent:
7244449, Jul 17, 2007
Filed:
Aug 29, 2002
Appl. No.:
10/230796
Inventors:
James L. Slater - Palo Alto CA, US
Gail T. Colbern - Pacifica CA, US
Peter K. Working - Burlingame CA, US
Gail T. Colbern - Pacifica CA, US
Peter K. Working - Burlingame CA, US
Assignee:
Alza Corporation - Mountain View CA
International Classification:
A61K 9/127
US Classification:
424450
Abstract:
A composition for administration of a therapeutically effective dose of a topoisomerase inhibitor I or topoisomerase I/II inhibitor is described. The composition includes liposomes having an outer surface and an inner surface defining an aqueous liposome compartment, and being composed of a vesicle-forming lipid and of a vesicle-forming lipid derivatized with a hydrophilic polymer to form a coating of hydrophilic polymer chains on both the inner and outer surfaces of the liposomes. Entrapped in the liposomes is the topoisomerase inhibitor at a concentration of at least about 0. 10 μmole drug per μmole lipid.
Liposome-Entrapped Topoisomerase Inhibitors
US Patent:
7279179, Oct 9, 2007
Filed:
Oct 8, 2004
Appl. No.:
10/962246
Inventors:
James L. Slater - Palo Alto CA, US
Gail T. Colbern - Pacifica CA, US
Peter K. Working - Burlingame CA, US
Gail T. Colbern - Pacifica CA, US
Peter K. Working - Burlingame CA, US
Assignee:
ALZA Corporation - Mountain View CA
International Classification:
A61K 9/127
US Classification:
424450
Abstract:
A composition for administration of a therapeutically effective dose of a topoisomerase inhibitor I or topoisomerase I/II inhibitor is described. The composition includes liposomes having an outer surface and an inner surface defining an aqueous liposome compartment, and being composed of a vesicle-forming lipid and of a vesicle-forming lipid derivatized with a hydrophilic polymer to form a coating of hydrophilic polymer chains on both the inner and outer surfaces of the liposomes. Entrapped in the liposomes is the topoisomerase inhibitor at a concentration of at least about 0. 10 μmole drug per μmole lipid.
Method For Potentiating Activity Of A Chemotherapeutic Drug
US Patent:
2005008, Apr 21, 2005
Filed:
Oct 12, 2004
Appl. No.:
10/964059
Inventors:
Francis Martin - San Francisco CA, US
Gail Colbern - Pacifica CA, US
Peter Working - Burlingame CA, US
Gail Colbern - Pacifica CA, US
Peter Working - Burlingame CA, US
International Classification:
A61K039/395, A61K033/24, A61K009/127, A61K031/704
US Classification:
424450000, 424649000, 514034000, 424143100
Abstract:
A method for potentiating the activity of a chemotherapeutic drug administered in combination with a biological agent is described. The method includes entrapping the chemotherapeutic drug in a liposome and administering the liposome-entrapped drug in combination with the biological agent. The method is particularly useful for treatment of cancer which over-express tyrosine kinase receptor and for B-cell lymphomas, where, for example, anti-HER2 antibodies or anti-CD19 antibodies are administered in combination with the cytotoxic drug.
Liposome-Entrapped Topoisomerase Inhibitors
US Patent:
2007023, Oct 4, 2007
Filed:
May 18, 2007
Appl. No.:
11/804484
Inventors:
James Slater - Palo Alto CA, US
Gail Colbern - Pacifica CA, US
Peter Working - Burlingame CA, US
Gail Colbern - Pacifica CA, US
Peter Working - Burlingame CA, US
International Classification:
A61K 9/127, A61K 31/4375, A61K 31/497
US Classification:
424450000, 514253020, 514283000
Abstract:
A composition for administration of a therapeutically effective dose of a topoisomerase inhibitor I or topoisomerase I/II inhibitor is described. The composition includes liposomes having an outer surface and an inner surface defining an aqueous liposome compartment, and being composed of a vesicle-forming lipid and of a vesicle-forming lipid derivatized with a hydrophilic polymer to form a coating of hydrophilic polymer chains on both the inner and outer surfaces of the liposomes. Entrapped in the liposomes is the topoisomerase inhibitor at a concentration of at least about 0.10 μmole drug per μmole lipid.
Bh55 Hyaluronidase
US Patent:
5747027, May 5, 1998
Filed:
Apr 7, 1995
Appl. No.:
8/419594
Inventors:
Robert Stern - San Francisco CA
Gregory I. Frost - San Francisco CA
Jackson Hall - San Francisco CA
Svetlana Shuster - San Francisco CA
Bent Formby - Santa Barbara CA
Gail T. Colbern - Pacifica CA
Gregory I. Frost - San Francisco CA
Jackson Hall - San Francisco CA
Svetlana Shuster - San Francisco CA
Bent Formby - Santa Barbara CA
Gail T. Colbern - Pacifica CA
Assignee:
The Regents of the University of California - Oakland CA
Sansum Medical Research Foundation - Santa Barbara CA
California Pacific Medical Center, Research Institute - San Francisco CA
Sansum Medical Research Foundation - Santa Barbara CA
California Pacific Medical Center, Research Institute - San Francisco CA
International Classification:
C12N 926, A61K 3846, A61K 3800
US Classification:
424 9462
Abstract:
The invention features a purified hyaluronidase BH55 polypeptide isolated from a mammalian species, preferably bovine or human. The invention also features DNA encoding BH55, vectors and transformed host cells containing DNA encoding BH55, the methods of making BH55 hyaluronidase polypeptides, and the antibodies that specifically bind BH55.
Bh55 Hyaluronidase
US Patent:
5827721, Oct 27, 1998
Filed:
Aug 27, 1997
Appl. No.:
8/919089
Inventors:
Robert Stern - San Francisco CA
Gregory I. Frost - San Francisco CA
Jackson Hall - San Francisco CA
Svetlana Shuster - San Francisco CA
Gail T. Colbern - Pacifica CA
Bent Formby - Santa Barbara CA
Gregory I. Frost - San Francisco CA
Jackson Hall - San Francisco CA
Svetlana Shuster - San Francisco CA
Gail T. Colbern - Pacifica CA
Bent Formby - Santa Barbara CA
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
C12N 926, C12N 1500, C12N 500, C07H 2104
US Classification:
435201
Abstract:
The invention features a purified hyaluronidase BH55 polypeptide isolated from a mammalian species, preferably bovine or human. The invention also features DNA encoding BH55, vectors and transformed host cells containing DNA encoding BH55, methods of making BH55 hyaluronidase polypeptides, and antibodies that specifically bind BH55.